Global Stem Cell Therapy Market, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 15,075.5 Million in 2022 and is expected to exhibit a CAGR of 21.2% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing product launches by key players such as medium for developing embryonic stem cells is expected to propel the market growth over the forecast period. For instance, in January 2019, STEMCELL Technologies, Biotechnology Company launched mTeSR Plus, a feeder-free human pluripotent stem cell (hPSC) maintenance medium for avoiding conditions associated with Deoxyribonucleic acid damage, genomic instability, and growth arrest in hPSCs. With the launch of mTeSR, the company has expanded its portfolio of mediums for maintenance of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.
Global Stem Cell Therapy Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global stem cell therapy market, owing to disruption in the supply chain and lack of raw material for developing new technology for stem cell therapy. For instance, in February 2021, according to the data published by the National Center for Biotechnology Information, the COVID-19 pandemic has caused significant disruption in the research, manufacturing, clinical development, and market launch of CGTs for non-COVID-19-related diseases. A shortage of supplies of materials for manufacturing, difficulties in clinical trials (e.g., patient recruitment, conduct of placebo-controlled trials, and follow-up), and a delay in regulatory dossier preparation are all contributing factors. This has emphasized the importance of addressing the challenges in the manufacturing and supply chain of CGTs to improve resilience during the crisis. The governments of different countries announced lockdown which imposed restriction on import and export activities and caused challenging situation for market players to developing stem cells therapies.
Global Stem Cell Therapy Market: Key Developments
In February 2022, EdiGene, Inc., a biotechnology company, collaborated with Neukio Biotherapeutics, a biotechnology company, for research and development of the next-generation immune cell therapies. The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s Biotherapeutics strength in the development and manufacturing of induced pluripotent stem cells (iPSCs) and natural killer cells (NK Cells).
In April 2022, Ncardia, a human iPSC technology company, launched a new business, Cellistic to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions, including the development of robust cell-specific manufacturing platforms. The development of cell therapies derived from iPSCs offers the possibility of effective treatments for many diseases and reducing the cost and complexity of current autologous cell therapies.
Browse 33 Market Data Tables and 21 Figures spread through 153 Pages and in-depth TOC on “Global Stem Cell Therapy Market”- Forecast to 2030, Global Stem Cell Therapy Market, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/stem-cell-therapy-market-2848
Moreover, increasing research and development of induced pluripotent stem cells coupled with clinical trials is expected to boost growth of the stem cell therapy market over the forecast period. For instance, in April 2019, Fate Therapeutics, Biotech Company in collaboration with UC San Diego, research university’s researchers launched Off-the-shelf immunotherapy (FT500) developed from human induced pluripotent stem cells. The therapy is undergoing clinical trials for the treatment of advanced solid tumors.
Key Takeaways of the Global Stem Cell Therapy Market:
- Global stem cell therapy market is expected to exhibit a CAGR of 21.2% during the forecast period due to the increasing adoption of inorganic strategies such as collaborations and agreements by the key players in market for developing stem cell therapy. For instance, in April 2022, Quell Therapeutics Limited, a biotechnology company, collaborated with Cellistic, a large-scale allogeneic cell therapy platform. The goal of the collaboration is to facilitate the future expansion of Quell's autologous Treg cell therapy pipeline by adding off-the-shelf, allogeneic Treg cell therapy products, leveraging Cellistic's expertise in differentiation and scale-up of iPSC processes for allogeneic cell therapy applications.
- Among regions, North America is estimated to account for the largest market share in the global stem cell therapy market over the forecast period, owing to the increasing number of clinical trials to cater to unmet medical needs of the patients. For instance, in April, 2019, UCLA-UCI Alpha Stem Cell Clinic participated in a new clinical research study to investigate a stem cell product CTX0E03 DP, in order to improve function in people with chronic disability from ischemic stroke. The study, called PISCES III, is currently in phase IIb clinical study. Moreover, manufacturers are focused on collaborating with academic researchers to help expand the potential use of newborn stem cell therapies that may be available to patients, which is expected to facilitate growth of market over the forecast period. Furthermore, in February 2018, the Institute of Integrative Biology entered into a collaboration with Anika Therapeutics, Inc., a global joint preservation company based in the U.S. to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis in patients.
- Europe is expected to witness significant growth in the global stem cell therapy market over the forecast period, owing to increasing number of product approvals by regulatory authorities and rising number of clinical trials in the region. For instance, in November 2018, Novartis AG, Pharmaceutical Company received an approval from the European Commission for its CAR-T (Kymriah) for treatment of B-cell acute lymphoblastic leukemia in pediatric and adult patients. Moreover, in January, 2019, the Center for Beta Cell Therapy in Diabetes and ViaCyte Inc. entered into a collaboration for their first European clinical trial involving human stem cell-derived implants among T1D patients. The trial was carried out by the Beta Cell Therapy Consortium with the support of Horizon 2020 grant from the European Commission.
- Asia Pacific is expected to witness significant growth in the stem cell therapy market over the forecast period, owing to increasing number of research programs and establishment of new stem cell banks in the region. For instance, in March 2019, the Chinese Academy of Sciences (CAS) announced the launch of three stem cell clinic research programs for treatment of severe eye diseases and gynecological diseases. The program was registered by the National Health Commission and the National Medical Products Administration. The stem cell research programs are majorly focused on treatment of retinal pigment degeneration, ovarian dysfunction, and intrauterine adhesions in women. Moreover, in January 2018, Lifecell Biotechnology, Biotechnology Company launched a stem cell bank in India, which preserves and provides umbilical cord stem cells for stem cell transplantation. In a stem cell transplantation therapy, damaged and diseased cell or tissues are replaced or repaired by using stem cells. Hence, increasing launches of stem cell banks is expected to drive the stem cell therapy market growth over the forecast period.
- Major players operating in the global stem cell therapy market include Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.
